期刊
PHARMACOGENOMICS
卷 9, 期 10, 页码 1437-1443出版社
FUTURE MEDICINE LTD
DOI: 10.2217/14622416.9.10.1437
关键词
dopamine; pharmacogenetics; risperidone; schizophrenia; serotonin
资金
- Japan Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labor and Welfare
- Core Research for Evolutional Science and Technology (CREST)
- Health Sciences Foundation
Aims: Abnormalities in dopaminergic and serotonergic transmission systems are thought to be involved in the pathophysiology of schizophrenia and the mechanisms underlying the therapeutic effects of antipsychotics. We conducted a pharmacogenetic study to evaluate whether variants in dopamine-related genes (DRDl-DRD5, AKT1 and GSK3 beta) and serotonin receptor genes (HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6 and HTR7) can be used to predict the efficacy of risperidone treatment for schizophrenia. Materials & methods: A total of 120 first-episode neuroleptic-naive schizophrenia patients were treated with risperidone monotherapy for 8 weeks and clinical symptoms were evaluated by the Positive and Negative Syndrome Scale. Results: Among the 30 variants that we examined, two SNPs in DRD2 (-241A>G [rs1799978] and TaqIA [rs1800497]) and two SNPs in AKT1 (AKT1-SNP1 [rs3803300] and AKT1-SNP5 [rs2494732]) were significant predictors of treatment response to risperidone. Conclusion: These data suggest that the SNPs in DRD2 and AKT1 may influence the treatment response to risperidone in schizophrenia patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据